ArticleScience (New York, N.Y.)2016
β-cell-mimetic designer cells provide closed-loop glycemic control.
Article in Science (New York, N.Y.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
106 citing papers in PubMed, 219 citations in OpenAlex.
- Article
- Article
- ERAD-level gene switches for on-demand protein secretion and rapidly controlled gene therapies.Nature communications · 2026Article
- A synthetic angiotensin II/ACE2-based hormone shunt controlling experimental hypertension.Nature communications · 2026Article
- Design and Modeling of Biosensor-Driven Encapsulation Systems for Systemic Delivery of Bacterial Cancer Therapy.ACS synthetic biology · 2026Article
- Traceless Regulation of Genetic Circuitry.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- PID-controller enhanced artificial β-cells.PloS one · 2026Article
- Engineering mammalian cells for detection and treatment of cardiac injury.Molecular systems biology · 2026Article
- Synthetic closed-loop gene circuit for phenylalanine regulation.Nucleic acids research · 2025Article
- Electromagnetic wireless remote control of mammalian transgene expression.Nature nanotechnology · 2025Article
- Nitroglycerin-responsive gene switch for the on-demand production of therapeutic proteins.Nature biomedical engineering · 2025Article
- Synthetic Biology-Based Engineering Cells for Drug Delivery.Exploration (Beijing, China) · 2025Review
- On-demand treatment of metabolic diseases by a synthetic drug-inducible exocytosis system.Nature communications · 2025Article
- Aspirin-responsive gene switch regulating therapeutic protein expression.Nature communications · 2025Article
- A Pro-Angiogenic Immunoprotective Membrane for Cell Therapies.Advanced healthcare materials · 2025Article
- Engineering signalling pathways in mammalian cells.Nature biomedical engineering · 2024Review
- A sensitive red/far-red photoswitch for controllable gene therapy in mouse models of metabolic diseases.Nature communications · 2024Article
- Ultrashort-Peptide-Responsive Gene Switches for Regulation of Therapeutic Protein Expression in Mammalian Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Engineering pluripotent stem cells with synthetic biology for regenerative medicine.Medical review (2021) · 2024Review
- Synthetic Gene Circuits for Regulation of Next-Generation Cell-Based Therapeutics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
46 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
Chronically deregulated blood-glucose concentrations in diabetes mellitus result from a loss of pancreatic insulin-producing β cells (type 1 diabetes, T1D) or from impaired insulin sensitivity of body cells and glucose-stimulated insulin release (type 2 diabetes, T2D). Here, we show that therapeutically applicable β-cell-mimetic designer cells can be established by minimal engineering of human cells. We achieved glucose responsiveness by a synthetic circuit that couples glycolysis-mediated calcium entry to an excitation-transcription system controlling therapeutic transgene expression. Implanted circuit-carrying cells corrected insulin deficiency and self-sufficiently abolished persistent hyperglycemia in T1D mice. Similarly, glucose-inducible glucagon-like peptide 1 transcription improved endogenous glucose-stimulated insulin release and glucose tolerance in T2D mice. These systems may enable a combination of diagnosis and treatment for diabetes mellitus therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.